You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection

Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan

FDA accepts Genentech's giredestrant application for early-stage breast cancer

Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC

Haisco receives US FDA approval for anaesthetic Cipepofol

Hanmi signs licensing deal with Lilly for sonefpeglutide

FDA approves TREMFYA label expansion

GSK reports positive phase III data for bepirovirsen in chronic hepatitis B

Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease

CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network

Ribo submits Phase 2 trial application for RBD1119 to European regulator

US FDA extends review timeline for AstraZeneca's camizestrant application

Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)

Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China

Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026